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Abstract: Introduction: Biosimilars have the potential to enhance the sustainability of evolving health
care systems. A sustainable biosimilars market requires all stakeholders to balance competition
and supply chain security. However, there is significant variation in the policies for pricing,
procurement, and use of biosimilars in the European Union. A modified Delphi process was conducted
to achieve expert consensus on biosimilar market sustainability in Europe. Methods: The priorities
of 11 stakeholders were explored in three stages: a brainstorming stage supported by a systematic
literature review (SLR) and key materials identified by the participants; development and review of
statements derived during brainstorming; and a facilitated roundtable discussion. Results: Participants
argued that a sustainable biosimilar market must deliver tangible and transparent benefits to the health
care system, while meeting the needs of all stakeholders. Key drivers of biosimilar market sustainability
included: (i) competition is more effective than regulation; (ii) there should be incentives to ensure
industry investment in biosimilar development and innovation; (iii) procurement processes must
avoid monopolies and minimize market disruption; and (iv) principles for procurement should be
defined by all stakeholders. However, findings from the SLR were limited, with significant gaps
on the impact of different tender models on supply risks, savings, and sustainability. Conclusions:
A sustainable biosimilar market means that all stakeholders benefit from appropriate and reliable
access to biological therapies. Failure to care for biosimilar market sustainability may impoverish
biosimilar development and offerings, eventually leading to increased cost for health care systems
and patients, with fewer resources for innovation.
Keywords: biosimilar market; biosimilar/supply and distribution; biosimilar sustainability;
Delphi technique
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1. Introduction
The global biosimilars market was valued at $4.5 billion in 2019 and is expected to reach $23.6
billion by 2024; this is an estimated growth rate of 39.4%, with most of this growth occurring in
Europe [1,2]. Such a rapid acceleration in the biosimilars market may result in numerous challenges,
and it is important to support a thoughtful deployment of biosimilars. This will provide an opportunity
for sustainability of global health care budgets and evolving health care systems [3,4].
At present, the European Medicines Agency (EMA) defines a “biosimilar” as “a biological
medicinal product that contains a version of the active substance of an already authorized original
biological medicinal product (reference medicinal product)” for which “similarity to the reference
medicinal product in terms of quality characteristics, biological activity, safety, and efficacy based on a
comprehensive comparability exercise needs to be established” [5,6]. Manufacturers in both the United
States and Europe are required to demonstrate that the proposed biosimilar and its reference product
are highly similar and have no clinically meaningful differences [5,7].
Thus, biosimilars are manufactured following the same strict standards of quality, safety, and efficacy
observed for the reference product [5,7]; this is reflected in the development cost, which ranges from
$100 to 300 million [8]. Biosimilars can broaden product choice and have the potential to reduce prices,
whilst continuing to support a high standard of patient care [9]. In the United States, potential cost saving
from switching from originator biologics to biosimilars is projected to be between $40 and 250 billion by
2025, and in Europe, cost savings are already estimated to be more than €10 billion [2,10–12].
Many organizations representing physicians, pharmacists, and patients across Europe support
the use of biosimilars [3,4,13–15], and have issued position papers outlining best practices for their
use. However, biosimilar markets are still evolving, and there are marked differences between policies
and practices across European countries [16–18]. For example, some payer bodies have implemented
single winner tender-based systems. While this can secure significant short-term payer savings,
such systems risk locking out many biosimilar manufacturers, and may limit the number of competing
manufacturers in the medium term. In addition, single-manufacturer tenders can place a lot of risk on
the supply chain and, potentially, on patient access. Therefore, systems need to be set up to ensure that
long-term savings are realized for payers and sufficient manufacturer incentives are in place to sustain
multiplayer competition. Further, the notion of biosimilar sustainability is currently inconsistently
and poorly defined, and there is a lack of awareness on the vulnerability of the current system. Previous
analyses of the biosimilars market have concluded that there is a need to improve sustainability,
and several areas have been identified for further research to develop a coherent long-term vision of
sustainability. These include safeguarding the interests of patients, maintaining physician autonomy
and patient choice, effective purchasing/pricing and reimbursement strategies, good pharmacovigilance
practices, and healthy levels of competition to ensure consistent supply of a range of high-quality
products [11,19,20].
To consider these issues and examine biosimilar market sustainability in more detail, we conducted
a systematic literature review (SLR) and Delphi panel discussion to: (i) establish a multistakeholder
definition of biosimilar market sustainability; (ii) further identify components of a sustainable biosimilar
market; and (iii) identify drivers and risks of a sustainable biosimilar market.
2. Methods
2.1. Design
The modified Delphi process is a commonly published approach to generate discussion around
topics without consensus and is an effective way to start dealing with complex multifactorial
challenges [21]. A modified Delphi process, involving 11 key opinion leaders representing various
sectors of the health care system in Europe, was conducted between September and November 2019.
Participating stakeholders comprised one patient advocate, two physicians, two hospital pharmacists,
two procurement pharmacists, one national payer, two policy advisors, and one manufacturer from
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across Europe. The modified Delphi process was based on a published approach, [22] and consisted of
brainstorming, structured feedback, and a facilitated roundtable discussion (Figure 1).
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2.2. Procedure
The Delphi process was initiated by multiple stages of brainstorming, in which participants
contributed their initial views by email and telephone using the questionnaire shown in Appendix A.
Participants were provided with stimulus materials identified by an SLR and they were also asked to
identify any key papers to support their feedback. The SLR is briefly described in this paper, but it is
published elsewhere [18].
The SLR was conducted using EMBASE, MEDLINE, and grey literature searches. The searches
were conducted using recent evidence (from 2008 to 2019) to capture all key biosimilar publications
after their introduction in Europe in 2006. Only publications in English were included. Search methods
were based on recommendations from the Cochrane Handbook [23] and the Centre for Reviews
and Dissemination [24]. The SLR identified materials relating to major economies in Europe
and answered three predefined key questions on the: (Q1) frequency, causes, and consequences
of shortages of reference product biologics and biosimilars; (Q2) costs (direct and indirect costs,
resource utilization, and external costs) and impacts resulting from switching patients between
biosimilar products; and (Q3) causation between tendering, market concentration, drug shortages,
and achievement of savings, and the implications of tender models for supply risk (reliability)
and sustainability of competitive biosimilar markets.
In an initial screening phase, one reviewer identified relevant titles and abstracts from among all
retrieved records; in a second screening stage, one reviewer re-evaluated each selected publication in a
full-text review. In both stages, a second reviewer was consulted in cases of uncertainty, and consensus
between the two was reached. Data extraction was performed by two reviewers, with one extracting
the data and the second checking the data against the original publication. Any discrepancies were
resolved through discussion or through the intervention of a third reviewer. The SLR flow chart is
shown in Appendix B. The findings of the SLR were provided to the panel during the brainstorming
stage; participants reviewed the material (amendments were allowed) and provided their ideas.
The feedback was discussed with each participant via telephone to ensure that it was interpreted
correctly, and the finalized brainstorming responses were collected via email. The amended stimulus
material is shown in Appendix C [3,4,16–18,25–27]. These references and the brainstorming responses
were used to develop the themes and statements for the second stage.
In the second stage of the Delphi process, the brainstorming responses and evidence extracted
from the stimulus materials were converted into themes and statements (Appendix D), using standard
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primary research methodology. Feedback was sought on: (i) the components for a definition of
biosimilar market sustainability and (ii) drivers and risks to achieving sustainability. Participants
were asked to indicate on a Likert scale (from “strongly disagree” to “strongly agree”) their level of
agreement with each theme and statement, and how strongly they felt the evidence supported each
theme and statement. Each participant had 1 week to provide their responses.
Stage 3 was a facilitated roundtable discussion that aimed to derive a multistakeholder definition
of sustainability and achieve consensus on the components of a sustainable biosimilar market.
First, the participants were presented with a definition of sustainability (derived from feedback
supplied in stage 2) and were then asked to provide feedback on the definition, stating their level of
agreement (“strongly disagree” to “strongly agree”), and providing any revisions they wished to make
in free text. Based on the responses, the initial definition was revised and presented to participants
for comment and final agreement at the end of the roundtable discussion. Participants were then
presented with eight statements on the components of a sustainable biosimilar market and on drivers
and risks to sustainability (derived from feedback supplied in stage 2). Participants were asked to
provide individual feedback regarding how much they agreed with each statement, how important
each statement was to them, and free-text suggestions on how to rephrase each statement so that it
would align better with their views. The purpose of the discussions on each statement was to explore
areas of agreement and disagreement between stakeholder groups. Where groups agreed, consensus
was noted; however, the process could cease if stakeholder views remained divergent.
3. Results
3.1. Delphi Panel Consensus
3.1.1. A Multistakeholder Definition of Biosimilar Market Sustainability
The multistakeholder consensus definition of a sustainable biosimilars market is provided
in Box 1. After much deliberation, this definition was agreed upon by all participants; however,
different stakeholder groups emphasized different priorities within this definition. Patients wanted to
be well-informed, physicians wanted biosimilar-related savings reinvested, pharmacists/manufacturers
emphasized quality, and payers/policy advisers focused on mechanisms (e.g., competition) to lower
prices. These differing priorities were not considered to be mutually exclusive, and all participants
considered it important to incorporate the perspectives of all stakeholders into the definition of a
sustainable biosimilar market in Europe.
Box 1. A multistakeholder consensus definition of a sustainable biosimilar market.
• A sustainable biosimilar market means that . . . “All stakeholders, including patients, benefit from
appropriate and reliable access to biological therapies. Competition leads to a long-term predictable price
level, without compromising quality, while delivering savings that may be reinvested.”
3.1.2. Components of a Sustainable Biosimilar Market
Participants agreed that a sustainable biosimilar market: (i) must deliver tangible and transparent
benefits to the health care system; (ii) must address the needs of all stakeholders; and (iii) requires
collaboration between stakeholders. The level of consensus achieved on these key points is summarized
in Box 2 and Table 1.
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Table 1. Consensus on components of a sustainable biosimilar market.
I. A sustainable biosimilar market must deliver tangible and transparent benefits to the health care system
Biosimilars have the potential to reduce the cost of treatment; this, in turn,
strengthens the sustainability of health care expenditure
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Table 1. Cont.
III. A sustainable biosimilar market requires collaboration between stakeholders
Policies and practices must encourage trust in biosimilar use among patients through
effective communication between stakeholders
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Box 2. Consensus on components of a sustainable biosimilar market.
A sustainable biosimilar market must:
• Deliver tangible and transparent benefits to the health care system, while
• Addressing the needs of all stakeholders
This requires collaboration between stakeholders.
In brief, participants strongly agreed that biosimilars have the potential to promote competition
among biologic options and reduce treatment costs. However, there was a need to identify and minimize
transition and disruption costs when switching to a biosimilar or between biosimilars to improve
savings associated with these products further. These savings should be tangible (i.e., measurable)
and reinvested in health care or other public services where possible. This could include budget deficits
and funding of innovative therapies; biosimilars have the potential to expand access [8]. Transparency
regarding reinvestment was regarded as another important motivator for physicians and patients to
use biosimilars. Minimizing transition costs could be achieved by identifying key differences between
therapeutic areas and clinical settings. For example, oncology treatments usually follow a short,
defined treatment course reducing the need for switch, whereas rheumatoid arthritis treatments may be
chronic with multiple use of biosimilars and combinations. Clear guidance (policies and practices) from
regulators and clinical organizations, such as the EMA, regarding biosimilar transition is warranted
with the need for real-world evidence based on biosimilars that physicians can effectively communicate
to patients to avoid any negative perceptions. Collaboration between stakeholders would help enable
any guidance to be consistent, more comprehensive, and more easily communicated.
3.1.3. Drivers and Risks of a Sustainable Biosimilar Market (Competition and Incentives)
The consensus achieved by participants regarding drivers and risks of a sustainable biosimilar
market is summarized in Box 3 and Table 2. Points of consensus were formulated as follows:
(i) competition is a more effective mechanism to achieve a long-term predictable price level than
regulation; (ii) there needs to be incentives for investment in future biosimilars; and (iii) government
and pricing bodies need to drive incentives.
For key market drivers, participants agreed that competition generated by the introduction of
biosimilars has been effective in reducing prices for biological therapies in Europe [28,29]. Participants
also agreed that the price expectations of decision makers must reflect market opportunity. This was
illustrated by the case of adalimumab biosimilars, the entry of which into the market in 2018 triggered
almost immediate and substantial discounting. However, adalimumab was used in a large patient
population and had achieved extremely high revenues prior to biosimilar entry, making it a very
attractive target for biosimilar manufacturers. Consequently, the price levels achieved by adalimumab
biosimilars might not be repeated in other biosimilar products, especially those with orphan status.
Incentives driven by governments and pricing bodies (such as limits on tender) were also identified as
key drivers for future market; these incentives could include procurement design, including contract
length, a cap on the number of manufacturers selected, and introduction of geographical divisions
(national vs. regional vs. local).
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Table 2. Consensus on drivers and risks to biosimilar market sustainability (competition and incentives).
I. Competition is a more effective mechanism to achieve a long-term predictable price level than regulation
Increased competition leads to more rapid price reduction and, if procurement
policies contribute to business continuity, a sustained lower price level
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Table 2. Cont.
II. There needs to be incentives for investment in future biosimilars
Continued investment in biosimilar development and market entry is important to
generate competition for biological therapies for which no biosimilar is currently
available and, to a lesser extent, therapies with biosimilars already available
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Box 3. Consensus on drivers of and risks to a sustainable biosimilar market.
• Competition is a more effective mechanism to achieve a long-term predictable price level, compared
to regulation
• There needs to be incentives for industry investment in future biosimilars
• Government and pricing bodies need to drive incentives
• Procurement processes should avoid monopolies and minimize patient discomfort and disruption to
the health care system
• The principles for procurement should be defined by all stakeholders.
For key market risks, there was agreement that there is a need for better indicators than those
currently available (e.g., the number of biosimilar manufacturers and manufacturing sites) to warn
of potential de facto monopoly [30]. Participants agreed that the emergence of monopolies could
lead to higher price levels and/or enhanced supply risks (such as poor quality), or supply shortages
(e.g., limited production capabilities and poor distribution channels) for biosimilars. This risk also
exists for generics, but it would be greater for biosimilars due to the lengthier development and market
entry processes, and the much longer lead time in manufacturing (1 year or more). Participants felt
that there was a need for more research to identify prospective indicators of market performance;
these should be based on a thorough understanding of the role that procurement level (national vs.
subnational (procurement is described below)), market size, number of awarded contracts (and market
share awarded), and tender criteria may play in ensuring markets perform well. Unfortunately,
published evidence on indicator performance or biosimilar supply risks and shortages are scarce
making generalizability difficult, but also highlighting the need for establishing validated approaches
to long-term quantification of these frameworks.
3.1.4. Drivers and Risks of a Sustainable Biosimilar Market (Procurement Processes)
Issues surrounding procurement processes are summarized in Box 3 and Table 3. Participants
agreed that procurement processes should avoid monopolies and minimize patient and health
care system disruption, and the principles for procurement should be agreed by all stakeholders.
The participants also identified two main goals of procurement design from a multistakeholder
perspective. The first goal was to prevent predatory behavior by considering factors in selection
criteria other than price or aggressive price discounting; these could include differentiation based
on formulation and quality attributes, or stock and distribution channels. The second goal was to
minimize disruptions to patient care based on the needs of individual therapy areas, perhaps by
setting a contract duration that is proportional to the duration of treatment. Given the potential
implications of procurement policies for all stakeholders, participants agreed that all stakeholders
should have a voice in setting procurement policies. Participants agreed that there cannot be a “one size
fits all” approach to procurement, as the structure and characteristics of health care systems vary;
however, procurement policies should be consistent, guided by a common set of principles, and abide
with European Union rules on tendering. Participants also advised that biosimilar procurement must
be managed carefully over the product lifecycle to preserve competition and promote new investment
in biosimilar development.
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Table 3. Consensus on drivers and risks to biosimilar market sustainability (procurement processes).
I. Procurement processes should avoid monopolies and minimize patient and health care system disruption
The emergence of monopolies may lead to higher price levels and/or enhanced
supply risks
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3.2. Key Findings from the SLR
A total of 36 studies were identified in the SLR (Appendix B). Nine publications were identified
that discussed (Q1). However, these were too limited to provide any comprehensive evidence
and demonstrate the lack of a consistent, comprehensive database of medicine shortages in Europe.
Nineteen publications addressed (Q2). None of these reported switching between biosimilars;
rather, all considered switches from a reference product to a biosimilar. Nine publications focused on
(Q3). These offered insufficient evidence from which to reach generalized conclusions about the effects of
different tender models on the outcomes of interest. However, one policy paper concluded that barriers
to entry, including the use of single-manufacturer tenders, will limit competition in biosimilars [16].
This paper was considered by the panel, together with additional evidence summarized in Appendix C.
4. Discussion
A Delphi process, involving diverse stakeholders from across Europe, was conducted to achieve
a consensus opinion on biosimilar market sustainability in Europe. Divergent views between
stakeholder groups, and the reasons for these, were explored through individual, anonymized
feedback and facilitated discussion at a roundtable meeting. This important exercise was undertaken
to increase our understanding of the current system and to address concerns regarding sustainability,
including the unmet need to develop a long-term vision, as highlighted in previous analyses [11,19,20].
Participants agreed that a sustainable biosimilar market must deliver tangible and transparent benefits
to the health care system, while meeting the needs of all stakeholders. The definition (as shown
in Box 1) was approved by all participants; however, different stakeholder groups emphasized
different priorities within this definition, which is consistent with the previous literature on a lack of
a unified approach [19,20]. Participants also agreed that, to make this approach work, collaboration
between stakeholders is required and a greater awareness of the drivers of and threats to a sustainable
market. In brief, strategies around competition, incentives, and procurement policies were identified
and discussed with key consensus highlighted in the tables. These areas (notably the need to establish
healthy competition, pricing, and market access policies (considering gain sharing and price reductions),
government policy and guidance, identification of risks associated with biosimilar drug supply
(e.g., quality issues), and patient access to information and education) were highlighted in the previous
literature as key areas requiring further improvements [11,19]. Participants in the Delphi process
agreed that these key findings should be developed further into a white paper that highlights the need
for multistakeholder collaboration on establishing principles for biosimilar procurement in Europe.
Several priorities for future research were identified by stakeholders. First, understanding
and measuring the impact of biosimilar transition on hospital and health care services will better
enable costs and benefits to be weighed up and help minimize disruption for patients and health
care services. Second, there is a need to understand and develop prospective indicators of market
sustainability and potential risks to competitive biosimilar markets, particularly the emergence of de
facto monopolies and supply risks. Finally, it will also be important to understand the implications
of procurement structure and design for biosimilar market sustainability, especially with regard to
how the procurement level (national vs. subnational), market size, number of awarded contracts
(and market share awarded), and tender criteria affect market sustainability.
There is currently very limited published evidence available to support detailed arguments in
the three priority areas described above, largely because there are limited data with which to conduct
analyses. Biosimilar markets are still relatively new in Europe, which means that the available data
relate to limited time periods and newly emerging trends that may be expected to mature over time.
Further, the currently available data (e.g., on supply shortages of biosimilars) are kept at the national
level; this allows cross-country comparisons but poses a challenge for pan-European analysis. It is
therefore recommended that any further research begins with a scoping phase, in which the available
data are reviewed in detail to assess their suitability for the proposed purpose. Further research would
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also benefit from a more quantifiable approach to the sustainability framework, allowing us to measure
the extent to which a biosimilar market in a specific jurisdiction can be effectively maintained.
Collaboration with stakeholders to develop principles for biosimilar procurement may be progressed
in tandem with further research. The objective of establishing processes is to ensure that the concerns of
all stakeholders—patients, physicians, pharmacists, payers, policy advisers, and manufacturers—are
considered in procurement design. In the absence of evidence, open communication and collaboration
between stakeholders may provide the necessary information that procurement decision makers need
to prevent risks to biosimilar market sustainability from materializing.
This Delphi process involved a limited number of stakeholders and, as with any Delphi exercise,
may also be biased by those who chose to participate [31]. For example, a number of issues were not
considered such as the evolution of the biosimilar production process over time. However, the process
encompassed evidence from a broad review of available literature and covered a broad range of
stakeholder perspectives. Despite a rigorous approach, the findings of the SLR indicated that there
was an absence of consistent, comprehensive information about drug shortages (specifically biosimilar
shortages) and the costs of switching to biosimilars in Europe; these gaps exacerbate a lack of evidence
regarding the impact of different tender models for savings, sustainable competition, and supply
risk. The panel identified eight key papers (Appendix C), some of which were not identified by
the SLR. The consensus reached by the Delphi process provides further direction for future research
into, and implementation of, potential strategies to support these different aspects of sustainability.
5. Conclusions
A sustainable biologics market including biosimilars is essential for ensuring that health
care savings are maintained into the future, both for existing molecules and those approaching
a loss of exclusivity. This Delphi approach resulted in a consensus definition of biosimilar market
sustainability in Europe, specified the components of a sustainable biosimilar market, and identified
key drivers and risks to sustainability. Crucially, participants in the Delphi process highlighted the need
for multistakeholder collaboration in designing policy and practice relating to biosimilars (including
procurement). Further research is required alongside stakeholder collaboration to inform biosimilar
policy and practice in alignment with the principles identified in this Delphi process. Failure to
care for biosimilar market sustainability may impoverish the biosimilar development and offerings,
eventually leading to increased cost for health care systems and patients, with fewer resources
for innovation.
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Appendix A
Table A1. Brainstorming questionnaire (Delphi process stage 1).
I. Define a sustainable biosimilar market in Europe from your perspective.
• What does a sustainable biosimilar market look like?
• Provide up to five key points
II. What factors contribute to, or create a risk to, biosimilar market sustainability?
• How important are each of these factors in achieving sustainability?
• Provide up to five key points and indicate how important they are to you (low/moderate/high)
III. How have biosimilars contributed to the sustainability of health care system(s)?
• Are you aware of any specific, direct benefits from biosimilars entering the market?
Appendix B
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Appendix C
Table A2. Key literature identified during brainstorming (Delphi process stage 1).
Topic Source References
Savings
(implications for health system
sustainability)
Systematic literature
review/targeted additional search Vulto A, et al. (2019) [18]
Sustainable competition Systematic literature review
Mestre-Ferrandiz J, et al. (2016) [16]
Dave CV, et al. (2017) [25]
Dave CV, et al. (2018) [26]
Access and pricing Targeted additional search Moorkens E, et al. (2017) [17]Kawalec P, et al. (2017) [27]
Procurement/purchasing Review of tender documents(2018) Vulto A, et al. (2019) [18]
Patient safety/use Targeted additional search Tabernero J, et al. (2016) [4]EULAR PARE (2018) [3]
Appendix D
Table A3. Themes and statements (Delphi process stage 2).
Presence of multiple suppliers on an ongoing
basis—although there is no “correct” number of suppliers
1. Biosimilars offer choice and are an important
savings opportunity that can benefit the health
care system broadly
Competition that is effective in reducing prices
for biologics/biosimilars to a sustainable level
2. The presence of multiple suppliers offers
benefits (with some trade-offs)
Shared decision making with payer, pharmacist,
physician, and patients around biosimilar use
3. Competition offers benefits (with
some trade-offs)
Reliable supply of biosimilars that meet appropriate
standards for quality
4. Effective implementation is necessary
for sustainability
Stability in procurement structure and approach
5. Excessive levels of competition have potential
to be detrimental to the future of competition in
biosimilars markets
Avoidance of price erosion that leads to market exit
and the emergence of monopolies or the consolidation
of suppliers
6. The level at which procurement happens has
consequences for the number of manufacturers
in the market—national versus sub-national
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